Pipeline

Overview

Overview


We are developing a pipeline of purpose-built, targeted medicines against genetic drivers of cancer. By designing highly selective medicines, we have the potential to deliver treatments that increase clinical benefit in genetically defined patient populations and fulfill the promise of precision medicine for appropriate patients.

Program Indication


Larotrectinib (LOXO-101) Cancers Harboring Alterations of Tropomyasin Receptor Kinase (TRK)

Preclinical
Phase 1
Phase 2
Registration
Phase 2 Basket Trial
Status: Adult/adolescent solid tumors with TRK fusions, currently enrolling
NCI-MATCH Trial
Status: Phase 2 Multi-Sponsor Umbrella Protocol Across >900 Sites Nationwide larotrectinib (LOXO-101) for TRK Fusions
Adult Phase 1 Trial
Status: Continue to follow enrolled TRK fusion patients; explore non-fusion TRK biology, currently enrolling
Pediatric Phase 1/2 Trial
Status: Pediatric Solid or Primary CNS Tumors, Currently Enrolling

LOXO-292 (RET inhibitor) Cancers Harboring Alterations of Rearranged During Transfection (RET)

Preclinical
Phase 1
Phase 2
Registration
LOXO-292 Phase 1 Trial
Status: Phase 1 trial currently enrolling

LOXO-195 (TRK inhibitor) Next-Generation TRK Inhibitor for Potential Acquired Resistance

Preclinical
Phase 1
Phase 2
Registration
LOXO-195 Phase 1/2 Trial
Status: Phase 1/2 trial currently enrolling

LOXO-305 (BTK Inhibitor) Highly selective, reversible BTK inhibitor for B-cell Cancers

Preclinical
Phase 1
Phase 2
Registration
Status: IND-enabling studies ongoing for an expected clinical trial initiation in 2018

FGFR Program Cancers Harboring Alterations of Fibroblast Growth Factor Receptor (FGFR)

Preclinical
Phase 1
Phase 2
Registration
Status: Lead Optimization